Keryx Biopharmaceuticals Inc fka KERX

[FredKerx]

IMO, the Yoshka/gwells-IR contact scenario being played-out on this public message board is becoming quite troubling - never seen anything quite like it. From my viewpoint, it’s potentially looking more and more like a badly orchestrated “screenplay” that reeks and lacks any serious consideration or credibility.

An anonymous poster, clearly shown to be highly questionable at best (read posting history), self-portraying himself as a chosen conduit between company and investors on a public message board. A self-designated conduit announcing in advance everytime he’s going to contact IR seems rather odd - a set-up sort of speak. Normally, an investor contacts IR privately for any particular personal inquiries he or she may have and, if he or she feels compelled to communicate/share what he or she feels is important, than a post will surface from time to time. But repeatedly announcing, promoting if you will, seems like an orchestrated sequence which raises serious questions. Not to mention, IMO, the 2 previous IR contact posts from poster Yoshka/gwells which seem like something from a bad comic “screenplay”. Go back and take a close look and analyze said posts, the questions posed and replies that go along with them. Quite telling, IMO.

Now, the “hooligan” surfaces with some story about visiting a nephro, asking about Auryxia, and remarks from nephro as follows, “It works great but it’s too expensive for most patients and we don’t use it for nondialysis patients.” (why should I take as credible some story from someone who, IMO, has zero credibility). Folks, don’t know what it looks like to you but, to me, it looks like a “screenplay” in an attempt to reconcile ongoing “machinations” since and including what ocurred last Nov. 7th, day IDA approval was announced and day of 3Q2017 earnings cc. A “screenplay” directed at down playing Auryxia commercialization due to pricing and nephros not prescribing for IDA. Folks, do your research, find numerous studies, surveys, and research conducted, “visit “i hate dialysis.com”. Auryxia iron component has played a role from way before IDA approval, pricing as much an issue with other binders, and Auryxia costs benefits associated with reduction in IV put on display repeatedly. Folks, as one example, please take a look at the following..

https://www.spherixglobalinsights.com/wp-content/uploads/2017/11/Spotlight_RTD_Renal-Anemia_Q3_2017_FINAL.pdf

The nephrologist story, IMO, a “screenplay” directed at an attempt to reconcile and/or distort and distract from “hostage” pps, SUPPOSED slow IDA uptake, Madison comments some 11 months ago stating they had prepared and ready for IDA commercialization and, as per Yoshka/gwells, IR stating “preparing almost 2 years for IDA launch and that was facilitated by the infrastructure in place in part that was developed for Auryxia for hyperphospetemia.” - and so forth and so on.

You see folks, IMO, NOTHING adds up, the incongruencies are plentiful. Quite peculiar is Keryx’s CFO, Scott Holmes, stating 2 months ago in 4Q2017 earnings cc, “we expect prescriptions for iron deficiency anemia to almost solely come through the IMS” - YET, Pinky’s SF Friday scripts #’s are Symphony and not IMS (hmmmm).

Btw, the “hostage” scenario continues.

ALL the above, in my opinion.